These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35506077)

  • 21. Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension.
    Bouzina H; Hesselstrand R; Rådegran G
    Pulm Circ; 2019; 9(4):2045894019895446. PubMed ID: 31908768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary Arterial Remodeling Is Related to the Risk Stratification and Right Ventricular-Pulmonary Arterial Coupling in Patients With Pulmonary Arterial Hypertension.
    Grignola JC; Domingo E; López-Meseguer M; Trujillo P; Bravo C; Pérez-Hoyos S; Roman A
    Front Physiol; 2021; 12():631326. PubMed ID: 34012405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan.
    Imai R; Adachi S; Yoshida M; Shimokata S; Nakano Y; Okumura N; Murohara T; Kondo T
    Can J Physiol Pharmacol; 2020 Sep; 98(9):653-658. PubMed ID: 32924564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review.
    Lokhorst C; van der Werf S; Berger RMF; Douwes JM
    Front Cardiovasc Med; 2022; 9():1035453. PubMed ID: 36440049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator.
    Ahmed A; Ahmed S; Kempe D; Rådegran G
    Eur Heart J Open; 2023 Mar; 3(2):oead012. PubMed ID: 36959867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension.
    Haddad F; Contrepois K; Amsallem M; Denault AY; Bernardo RJ; Jha A; Taylor S; Arthur Ataam J; Mercier O; Kuznetsova T; Vonk Noordegraaf A; Zamanian RT; Sweatt AJ
    Chest; 2022 May; 161(5):1347-1359. PubMed ID: 34774527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
    Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
    Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
    Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.
    Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O
    Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early risk prediction in idiopathic
    Hjalmarsson C; Kjellström B; Jansson K; Nisell M; Kylhammar D; Kavianipour M; Rådegran G; Söderberg S; Wikström G; Wuttge DM; Hesselstrand R
    ERJ Open Res; 2021 Jul; 7(3):. PubMed ID: 34350280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
    Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension.
    Ahmed A; Ahmed S; Rådegran G
    Pulm Circ; 2021; 11(4):20458940211041500. PubMed ID: 34616545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension.
    Arvidsson M; Ahmed A; Bouzina H; Rådegran G
    Pulm Circ; 2019; 9(4):2045894019895414. PubMed ID: 31908766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.
    Lorente L; Martín MM; Labarta L; Díaz C; Solé-Violán J; Blanquer J; Orbe J; Rodríguez JA; Jiménez A; Borreguero-León JM; Belmonte F; Medina JC; Llimiñana MC; Ferrer-Agüero JM; Ferreres J; Mora ML; Lubillo S; Sánchez M; Barrios Y; Sierra A; Páramo JA
    Crit Care; 2009; 13(5):R158. PubMed ID: 19799791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit.
    Garcia MVF; Souza R; Costa ELV; Fernandes CJCS; Jardim CVP; Caruso P
    Respir Med; 2021 Dec; 190():106685. PubMed ID: 34823189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 levels in children with primary hypertension.
    Niemirska A; Litwin M; Trojanek J; Gackowska L; Kubiszewska I; Wierzbicka A; Kułaga Z; Michałkiewicz J
    J Hypertens; 2016 Sep; 34(9):1815-22. PubMed ID: 27379542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of calcium-sensing receptors in hypoxia-induced vascular remodeling and pulmonary hypertension by promoting phenotypic modulation of small pulmonary arteries.
    Peng X; Li HX; Shao HJ; Li GW; Sun J; Xi YH; Li HZ; Wang XY; Wang LN; Bai SZ; Zhang WH; Zhang L; Yang GD; Wu LY; Wang R; Xu CQ
    Mol Cell Biochem; 2014 Nov; 396(1-2):87-98. PubMed ID: 25063217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension.
    Daly CM; Griffiths M; Simpson CE; Yang J; Damico RL; Vaidya RD; Williams M; Brandal S; Jone PN; Polsen C; Ivy DD; Austin ED; Nichols WC; Pauciulo MW; Lutz K; Nies MK; Rosenzweig EB; Hirsch R; Yung D; Everett AD
    J Am Heart Assoc; 2021 Oct; 10(20):e021409. PubMed ID: 34622662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs.
    Valentin S; Maurac A; Sitbon O; Beurnier A; Gomez E; Guillaumot A; Textoris L; Fay R; Savale L; Jaïs X; Montani D; Picard F; Mornex JF; Prevot G; Chabot F; Humbert M; Chaouat A
    Eur Respir J; 2021 Oct; 58(5):. PubMed ID: 33875491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension.
    Simpson CE; Griffiths M; Yang J; Nies MK; Vaidya RD; Brandal S; Martin LJ; Pauciulo MW; Lutz KA; Coleman AW; Austin ED; Ivy DD; Nichols WC; Everett AD; Hassoun PM; Damico RL
    ERJ Open Res; 2021 Oct; 7(4):. PubMed ID: 34651041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.